Biogen
BIIB
1,059 hedge funds and large institutions have $31.6B invested in Biogen in 2026 Q3 according to their latest regulatory filings, with 107 funds opening new positions, 418 increasing their positions, 339 reducing their positions, and 71 closing their positions.
51% more first-time investments, than exits
New positions opened: 107 | Existing positions closed: 71
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
23% more repeat investments, than reductions
Existing positions increased: 418 | Existing positions reduced: 339
20% more call options, than puts
Call options by funds: $433M | Put options by funds: $361M
1% more funds holding
Funds holding: 1,051 → 1,059 (+8)
2.09% less ownership
Funds ownership: 96.94% → 94.85% (-2.1%)
16% less capital inflows, than outflows
Capital inflows: $1.92B | Capital outflows: $2.29B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$249M |
| 2 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$143M |
| 3 |
Farallon Capital Management
San Francisco,
California
|
+$129M |
| 4 |
Bellevue Group
Kuesnacht,
Switzerland
|
+$127M |
| 5 |
B. Metzler seel. Sohn & Co
Frankfurt,
Germany
|
+$83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$305M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$143M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$106M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$90.4M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
-$76.8M |
BIIB Hedge Fund Activity: Q3 2026 in Review
1,059 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2026, worth a combined $31.6B — up 2.4% from $30.9B a quarter earlier.
Buyers outnumbered sellers: 107 funds opened new BIIB positions and 71 closed out — a net gain of 36 holders — while 418 added to existing stakes and 339 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $249M. The largest seller was Fidelity Investments, cutting an estimated $305M.
- 1,059 institutional investors held Biogen (BIIB) as of Q3 2026, up from 1,051 in Q2 2026.
- Funds reported $31.6B of Biogen stock for Q3 2026, up 2.4% quarter-over-quarter.
- 107 funds opened new Biogen positions in Q3 2026 and 71 closed out, a net change of +36 holders.
- The largest Biogen buyer in Q3 2026 was Citadel Advisors, an estimated $249M added.
- The largest Biogen seller in Q3 2026 was Fidelity Investments, an estimated $305M sold.
Based on aggregated 13F filings for Q3 2026.